Furthermore, another potentially relevant clinical implication of this study is the evidence that addition of silybin to regorafenib treatment at the occurrence of regorafenib-induced liver toxicity, was associated with a statistically significant decreasing in the serum level of AST, ALT and bilirubin. The gene discussed is GPT; the disease is hepatotoxicity.